Until now, experts have believed it was necessary to compromise the control of bleeding to prevent thrombosis," said Michael Pierschbacher, senior vice president and scientific director of Telios of San Diego
The researchers injected chimpanzees with low doses of endotoxin to "recapitulate the process of coagulation that occurs in septic shock," Howard Soule, vice president of product development for Corvas of San Diego, told BioWorld
raised $41.25 million in an initial public offering of 3.75 million shares completed Wednesday, David Robinson, the San Diego company's president and chief executive officer, told BioWorld
Privately held Vical of San Diego is developing technology for the administration of polynucleotide and gene-based drug products to treat and prevent infectious and cardiovascular diseases, autoimmune disorders and cancer. -- Michelle Slade (c) 1997 American Health Consultants
Laboratories for Molecular Design is using proprietary technology to develop non-peptide drugs from peptide lead compounds that may be potential treatments for cardiovascular conditions, the company reported Thursday at the Connect San Diego Biotechnology Forum in La Jolla, Calif...Formed in June 1991, the privately held San Diego company is looking for research partners for its NPY drug development program, and to develop new molecules based on peptide structures using its Alanet technology
scientists reported their ongoing, unpublished gene therapy results in animal models of cancer at this week's First International Conference on Gene Therapy of Cancer, sponsored by the University of California, San Diego...Direct vaccination with retroviral vectors containing gene sequences for cancer-associated viral and human proteins resulted in significant protection of animals against challenge with viable tumor cells," the San Diego company said
Cytel (NASDAQ:CYTL) of San Diego is developing immunotherapeutics based on specific immune receptors critical in the early stages of the immune response. (c) 1997 American Health Consultants
of San Diego announced today that it has acquired rights to two separate gene therapy technologies that are being developed at the University of Chicago and at the University of Michigan
The six-month Phase I study will investigate optimal conditions for immunization of human lymphocytes prior to and after transferring these cells to surrogate human mice," according to David Katz, the San Diego company's president and chief executive officer
Neuroscientist Fred Gage, University of California, San Diego...Molecular biologist and virologist Inder Verma, Salk Institute, San Diego Mulligan collaborates with oncologist Drew Pardoll of Johns Hopkins University School of Medicine, who will conduct the impending cancer clinical trials
Detection of viral GB 2 254 424 San Diego gene sequences Indicator cell comprises genome coding for marker gene and control sequences, to test for virus carrying gene of interest
The formulation, G-203, is a patented fluocinonide single-use wipe designed to localize the corticosteroid at the site of application, the San Diego company said
of San Diego appointed Lloyd E. Flanders vice president, research and development planning, administration and project management...of San Diego appointed Michael E. Herman to its board of directors
Until now, experts have believed it was necessary to compromise the control of bleeding to prevent thrombosis," said Michael Pierschbacher, senior vice president and scientific director of Telios of San Diego